Back to top
more

Artivion (AORT)

(Delayed Data from NYSE)

$26.77 USD

26.77
464,683

+0.10 (0.37%)

Updated Aug 28, 2026 04:00 PM ET

After-Market: $26.74 -0.03 (-0.11%) 7:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (103 out of 248)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Masimo Stock in Your Portfolio Now

by Zacks Equity Research

MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.

Zacks Equity Research

RBOT Enters Strategic Software Partnership to Streamline Development

by Zacks Equity Research

Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.

Zacks Equity Research

Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Idexx Laboratories (IDXX) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Equity Research

EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy

by Zacks Equity Research

Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.

Zacks Equity Research

HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases

by Zacks Equity Research

Hologic shares dip as the company unveils new study data showing its Genius AI mammography flags 32% of previously missed breast cancer cases.

Zacks Equity Research

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Equity Research

ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries

by Zacks Equity Research

Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.

Zacks Equity Research

PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor

by Zacks Equity Research

Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.

Zacks Equity Research

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.

Zacks Equity Research

Artivion (AORT) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of +14.29% and +1.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?